Ernexa Therapeutics Inc. short interest in 2022
In 2022, Ernexa Therapeutics Inc.'s disclosed short interest ran from 4.15% of shares outstanding on 14 Jan 2022 to 1.56% on 14 Oct 2022, a change of -2.59 percentage points. The year's high was 6.02% on 31 May 2022 and its low 1.56% on 14 Oct 2022, averaging 3.91% across 19 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 9.22 days on 28 Feb 2022. Full history: Ernexa Therapeutics Inc..
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2022 in figures
- Start of year
- 4.15% (14 Jan 2022)
- End of year
- 1.56% (14 Oct 2022)
- Change
- -2.59 pp
- High
- 6.02% (31 May 2022)
- Low
- 1.56% (14 Oct 2022)
- Average
- 3.91%
- Highest days to cover
- 9.22 (28 Feb 2022)
- SEC filings marked
- 5
Every report in 2022
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 14 Jan 2022 | 4.15% | 4.56 | |
| 31 Jan 2022 | 4.03% | 4.71 | |
| 15 Feb 2022 | 4.32% | 6.82 | |
| 28 Feb 2022 | 4.96% | 9.22 | |
| 15 Mar 2022 | 4.85% | 7.66 | |
| 31 Mar 2022 | 4.41% | 4.60 | |
| 14 Apr 2022 | 3.91% | 5.33 | |
| 29 Apr 2022 | 4.86% | 6.21 | 10-K filed, results (8-K) |
| 13 May 2022 | 5.05% | 4.44 | |
| 31 May 2022 | 6.02% | 5.95 | |
| 15 Jun 2022 | 5.80% | 5.38 | |
| 30 Jun 2022 | 3.98% | 2.45 | |
| 15 Jul 2022 | 3.88% | 4.00 | 10-Q filed |
| 29 Jul 2022 | 3.83% | 6.12 | |
| 15 Aug 2022 | 3.27% | 3.60 | 10-Q filed |
| 31 Aug 2022 | 1.92% | 3.11 | |
| 15 Sep 2022 | 1.74% | 1.37 | |
| 30 Sep 2022 | 1.70% | 1.82 | |
| 14 Oct 2022 | 1.56% | 1.40 |
See also: Ernexa Therapeutics Inc.'s full history · most shorted US stocks of 2022 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.